Disc Medicine, Inc. (NASDAQ: IRON ) receives an average rating of “Moderate Buy” from analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON – Get Your Free Report ) has been assigned an average rating of “Moderate Buy” by the eight analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $64.13.

A number of research firms recently commented on IRON. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research report on Wednesday, July 10th. Cantor Fitzgerald restated an “overweight” rating and set a $85.00 target price on shares of Disc Medicine in a report on Tuesday, May 28th. Wells Fargo & Company assumed coverage on shares of Disc Medicine in a report on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 price target for the company. Raymond James lifted their price objective on shares of Disc Medicine from $40.00 to $43.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Finally, Wedbush restated an “outperform” rating and issued a $57.00 target price on shares of Disc Medicine in a research note on Friday, August 9th.

Read our latest research report on FIER

Institutional Disc Medicine Trade

Institutional investors have recently made changes to their positions in the business. Amalgamated Bank boosted its stake in Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock valued at $26,000 after buying an additional 247 shares in the last quarter. AJOVista LLC bought a new position in shares of Disc Medicine in the 4th quarter valued at about $63,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Disc Medicine in the second quarter valued at about $129,000. SG Americas Securities LLC boosted its holdings in Disc Medicine by 44.2% in the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock worth $183,000 after acquiring an additional 1,247 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in Disc Medicine in the 1st quarter worth about $211,000. Institutional investors own 83.70% of the company’s shares.

Medicine disk stock performance

Shares of NASDAQ:IRON opened at $50.82 on Friday. The company has a 50 day moving average price of $45.95 and a two hundred day moving average price of $45.05. The company has a market cap of $1.26 billion, a PE ratio of -15.04 and a beta of 0.57. Disc Medicine has a 52-week low of $25.60 and a 52-week high of $77.60.

Disc Medicine (NASDAQ: IRON – Get Free Report ) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. On average, sell-side analysts forecast that Disc Medicine will post -4.47 earnings per share for the current year.

Disc Medicine Company Profile

(Get a free report

Disc Medicine, Inc., together with its subsidiaries, is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of novel treatments for patients suffering from serious hematological diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to alter fundamental biological pathways associated with red blood cell formation and function, primarily heme biosynthesis and iron homeostasis.

Read more

Receive daily Disc Medicine news and reviews – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Disc Medicine and related companies with MarketBeat.com’s FREE daily email newsletter.